The Company

ILiAD Biotechnologies is a clinical-stage biotechnology company developing a next-generation vaccine to prevent disease caused by *Bordetella pertussis*, the bacterium responsible for whooping cough. Despite widespread vaccination, pertussis remains a significant global health challenge due to waning immunity and the limited ability of current acellular vaccines to prevent transmission.

ILiAD's vaccine candidate, BPZE1, is a live attenuated intranasal pertussis vaccine designed to mimic natural infection and stimulate both mucosal immunity in the respiratory tract and systemic immune responses in the bloodstream. This approach has the potential to provide broader and more durable protection compared to existing intramuscular acellular pertussis vaccines. BPZE1 is the most advanced next-generation pertussis vaccine in development and has completed multiple Phase 2 clinical trials, including a human challenge study demonstrating protection against virulent *B. pertussis*.

Founded in 2012, ILiAD has secured over $215 million in funding to support the development of BPZE1 and recently completed additional financing to further advance its clinical programs and manufacturing readiness. The company also operates BioLyo Technologies, a wholly owned subsidiary based in Ghent, Belgium, focused on process and analytical development for live bacterial products. Through its vaccine platform, ILiAD aims to address the persistent global burden of pertussis and deliver more effective prevention strategies for this highly contagious respiratory disease.

The Role

Iliad Biotechnologies is seeking a **Vice President, Clinical Development** to serve as a senior, hands-on clinical leader and trusted partner to executive leadership. This individual will take full ownership of day-to-day clinical development activities, stepping in to lead and execute workstreams currently managed at the executive level while helping guide the overall development strategy for the company's lead program.

This role is centered on late-stage clinical development, with an immediate focus on Phase 3 execution. The VP will combine deep operational involvement—authoring protocols and CSRs, overseeing studies and CROs, and making critical study decisions—with strategic input into program direction, publication planning, and future medical affairs needs.

The ideal candidate is highly autonomous, accountable, and comfortable operating in a build-stage environment—someone who can independently run clinical activities, make sound judgments in complex studies, and "roll up their sleeves" to deliver high-quality outputs. Over time, this individual will play an expanding leadership role within the global program team and help build the clinical development and medical affairs infrastructure.

iliadbio.com
info@iliadbiotech.com
800 603-3525

4581 Weston Road
Suite 260
Weston, FL 33331

Responsibilities

- Lead clinical development planning and broader program direction.
- Serve as a thought partner to executive leadership, independently driving clinical workstreams with strong judgment and accountability.
- Contribute as a clinical leader within the global program team (GPT).
- Take full ownership of day-to-day clinical development activities across late-stage programs (Phase 2–3 through approval).
- Lead execution of Phase 3 clinical studies from a clinical development perspective, including oversight of relevant CROs and external vendors.
- Ensure studies are executed efficiently, compliantly, and in alignment with program and protocol objectives.
- Monitor study conduct and data quality.
- Provide medical monitoring oversight, including subject-level review and protocol interpretation.
- Author and review clinical protocols, CSRs, and other key regulatory documents with a high standard of quality.
- Lead and execute publication planning in coordination with cross-functional stakeholders.
- Contribute to shaping the medical affairs strategy including scientific communications, education, and campaign development, as the program advances.
- Build and lead a clinical development team over time, including future medical writing and medical affairs capabilities.
- Establish processes and infrastructure to support scaling clinical and medical functions.
- Operate effectively in a matrixed environment driving alignment across functions including but not limited to: Clinical Operations, Regulatory, Medical Affairs, Commercial, and Project Management.

Qualifications and Experience

- MD strongly preferred; PhD considered with relevant experience.
- 15 years of clinical experience in pharmaceutical and/or biotech environments.
- Significant experience in late-stage clinical development (Phase 2–3 through approval), including leadership of Phase 3 studies.
- Deep expertise in clinical document authorship, including protocols, CSRs, and other key regulatory documents, with a high standard of scientific rigor and clarity.
- Experience managing CROs and external partners to deliver high-quality studies.
- Experience working closely with Regulatory Affairs to support clinical strategy, study design, and regulatory submissions. Experience supporting interactions with agencies such as FDA/EMA/MHRA.
- Proven ability to operate with high autonomy and accountability, owning deliverables end-to-end.
- Experience working in matrixed environments and contributing to global program teams.
- Experience supporting publication planning and scientific communications; broader medical affairs exposure (e.g., education, launch readiness) is a plus.
- Experience in vaccine development strongly preferred.
- Demonstrated potential to build and lead teams as the organization grows.
- Excellent written and verbal communication skills; native or near-native English proficiency required.
- East Coast location strongly preferred to support global study coordination.